TY - JOUR T1 - Apremilast Use in Oligoarticular Psoriatic Arthritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 1293 LP - 1294 DO - 10.3899/jrheum.211227 VL - 49 IS - 11 AU - Vicenç Torrente-Segarra AU - Maria Bonet Y1 - 2022/11/01 UR - http://www.jrheum.org/content/49/11/1293.abstract N2 - To the Editor:We read with interest the article published in The Journal of Rheumatology by Ogdie et al1 in which apremilast monotherapy showed more benefit in a specific subset of the psoriatic arthritis (PsA) population (oligoarticular pattern), compared to methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDs). The authors collected baseline and follow-up data (6-month period) regarding the clinical response to either MTX, apremilast, or bDMARD, all in monotherapy. A total of 150 patients with oligoarticular PsA (≤ 4 swollen joints) fulfilled inclusion criteria and were enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry.2 The authors found higher levels of clinical involvement and patient-reported outcome measures among patients who received apremilast compared to those who received MTX or bDMARD. Despite these data, apremilast (n = 34) showed better numerical clinical outcomes than both MTX and bDMARD in oligoarticular PsA (no statistical tests were performed). Accordingly, Mekhail et … Address correspondence to Dr. V. Torrente-Segarra, Rheumatology Department, Hospital Comarcal Alt Penedès-Garraf (CSAPG), Vilafranca del Penedès, Espirall s/n, 08720 Vilafranca del Penedès, Barcelona, Spain. Email: vtorrente{at}csap.cat. ER -